BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces the commercial release of LENS API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.

More details on this new offering will be unveiled at 2:00 pm ET, with an additional presentation, live demonstration, and interview at 6:30 pm ET, all taking place at the InterSystems Global Summit 2024. This premier event, which attracts over 1,200 industry leaders from more than 28 countries, showcases the latest innovations in the field.

IPA, the #1 ranked contract research organization by Roots Analysis², serves 19 of the top 20 global pharmaceutical companies and over 600 clients in the pharmaceutical and biotech industries. Leveraging feedback from these long-term relationships, the development of this AI-driven software is in direct response to meeting ongoing industry pain points and needs. These new software capabilities demonstrate innovation by combining BioStrand’s patented LENS^ai technology with electronic health records through a customizable interface to enable unprecedented research and drug discovery capabilities.

Also Read: Exscientia Appoints John P. Overington as Chief Technology Officer & Maria-Louise Fjällskog as Interim Chief Medical Officer

Dr. Dirk Van Hyfte is leading the launch of this exciting integration, enabling industry professionals to quickly and easily access and merge patient data, company research data, and extensive life science databases. Through this new release, corporations will be able to analyze major datasets related to generating novel and potentially safer and more effective drugs, as the BioStrand team continues to develop a full LENS^ai data management platform, expected to be released in Q1/Q2 2025.

Dr. Dirk Van Hyfte stated, “We have received significant interest in our new technology from large healthcare, pharmaceutical, and technology companies. They are keen on accessing our unique capabilities through an integration that enables them to benefit directly from BioStrand’s novel applications for data analysis and cutting-edge drug discovery. The Company regards the commercial launch of this pioneering software as its most significant AI breakthrough to date, poised to significantly enhance global drug discovery and development processes. By integrating BioStrand’s software with electronic health records, and adding BioStrand’s application programming interface, we have surpassed internal timelines and milestones, supporting the rapid commercialization of these high-demand capabilities.”

These new commercial capabilities will significantly enhance BioStrand’s ability to commercialize:

1. Partnerships with Large Companies: Major pharmaceutical, technology, and healthcare companies will be able to rapidly leverage BioStrand’s new software capabilities through partnerships that may include upfront payments, clinical milestones and commercial royalties.
2. Subscription Model: BioStrand is offering a subscription service that enables a wide range of technology, healthcare, and pharmaceutical companies to access BioStrand’s unique capabilities using integration of the software into their existing platforms, with a strong probability of enhancing their drug discovery and development programs.

Source: Businesswire